MIAMI, July 13, 2020 /PRNewswire/ -- INSIGHTEC, a global medical technology innovator of incisionless surgery, announced today achievement of complete Medicare coverage across all 50 states for MR-guided focused ultrasound treatment of medication-refractory Essential Tremor.
"INSIGHTEC is committed to expanding patient access for MR-guided focused ultrasound," said Dee Kolanek, INSIGHTEC Vice President of Reimbursement. "The efforts of our team have made complete Medicare coverage a reality by working closely with the seven Local Medicare Administrative Contractors over the last 18 months."
Compelling clinical evidence and support from physicians, specialty societies and patients led to positive coverage decisions in the final two jurisdictions, resulting in full Medicare coverage across the country.
"Complete Medicare coverage is a significant milestone for INSIGHTEC and brings the incisionless treatment option to millions of people," commented Maurice R. Ferré MD, INSIGHTEC'S CEO and Chairman of the Board of Directors. "This is the critical next step in our mission to make focused ultrasound a standard of care to improve the lives of people living with a challenging condition."
Essential Tremor is a movement disorder affecting an estimated ten million Americans. INSIGHTEC's MR-guided focused ultrasound has been FDA-approved since 2016 for the treatment of medication-refractory Essential Tremor. The treatment is performed with INSIGHTEC's Exablate Neuro platform, which delivers ultrasound waves to precisely ablate the target tissue with no incisions necessary. Many patients show immediate tremor relief with minimal complications. There are 22 treatment centers in the United States currently treating patients on a regular basis.
INSIGHTEC is a global medical technology innovator transforming patient lives through incisionless brain surgery using focused ultrasound guided by MR imaging. The company's award-winning Exablate Neuro device is FDA-approved to treat medication-refractory Essential Tremor and Tremor-dominant Parkinson's Disease. Research for future applications in the neuroscience space is underway in partnership with leading academic and medical institutions. INSIGHTEC is headquartered in Haifa, Israel, and Miami, Florida, with offices in Dallas, Shanghai and Tokyo.
This document contains forward-looking statements regarding, among other things, plans, expectations, and future events. In some cases, forward-looking statements can be identified by the following words: "may," "can," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "promise," "continue," "ongoing," or the negative of these terms. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. Any forward-looking statement is based on information available to INSIGHTEC as of the date of the statement. All written or oral forward-looking statements attributable to INSIGHTEC are qualified by this caution. INSIGHTEC does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in INSIGHTEC's expectations.
"Exablate," and "Exablate Neuro," as well as the "INSIGHTEC" logo, whether standing alone or in connection with the word " INSIGHTEC", are protected trademarks of INSIGHTEC.
INSIGHTEC Media Contact
G&S Business Communications for INSIGHTEC Lyndsay Isaksen +1-917-595-3032 [email protected]